Raashid Luqmani, DM
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Raashid Luqmani, DM, Rheumatology Department, Nuffield Orthopaedic Centre, Windmill Road, Oxford OX3 7LD, United Kingdom; e-mail, email@example.com.
Luqmani R. Treatment of Polymyalgia Rheumatica and Giant Cell Arteritis: Are We Any Further Forward?. Ann Intern Med. 2007;146:674-676. doi: 10.7326/0003-4819-146-9-200705010-00011
Download citation file:
Published: Ann Intern Med. 2007;146(9):674-676.
Giant cell arteritis (GCA) and polymyalgia rheumatica are common overlapping inflammatory rheumatic diseases of unknown cause that share some clinical features and affect patients older than 50 years. The age-adjusted annual incidence of GCA is 188 to 220 cases per 1 million persons (1, 2) in the United States and the United Kingdom and 290 per 1 million persons in Norway (3). The annual incidence of polymyalgia rheumatica varies from 120 per 1 million persons in Italy (4) to 1120 per million in Norway (3) and is higher in women than men.
Learn more about subscription options.
Register Now for a free account.
Rheumatology, Giant Cell Arteritis/Polymyalgia Rheumatica.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only